Compugen Ltd. · NASDAQ:CGEN
Compugen — Bio-Tech Israel 2004
17 slides from Compugen's conference presentation, May 5, 2004
Slide 1: Compugen: Increasing the Probability of Success in Drug Discovery
Compugen: Increasing the Probability of Success in Drug Discovery Mor Amitai Bio-Tech Israel May 5, 2004
Slide 2: Agenda
Agenda • R&D Process • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Business Model
Slide 3: Probability Of Success (POS)
Probability Of Success (POS) • POS: The chances a given discovery will result in a product • Our mission – To increase the probability of success of drug and diagnostic development by incorporating ideas and methods from mathematics, computer science, and physics into the disciplines of biology, org
Slide 4: What We Do
What We Do • Build technologies that address POS- critical components in the drug discovery process • Current major technologies: – Genomic infrastructure platforms – Discovery engines: therapeutic proteins and biomarkers – Lead discovery technology
Slide 5: R&D Process
R&D Process Analysis, mathematical modeling, predictions Lab studies, Computational validation, Manual proof
Slide 6: The LEADS Process
The LEADS Process • Computational biology platform • Used by, among others: • Unique modeling of biological phenomena
Slide 7: Alternative Splicing
Alternative Splicing Science. May 2003 Genome Res. July 2003 Trends in Genetics. February 2004 Molecular Cell. April 2004
Slide 8: Antisense
Antisense
Slide 9: Therapeutic Discovery Engines
Therapeutic Discovery Engines LEADS Engine monitored and improved
Slide 10: Initial Pipeline
Initial Pipeline • VEGF-114 • PSA-LM and K-LM • CGEN-40 • CGEN-G11 • CGEN-B2 Six additional proteins to be added this year
Slide 11: VEGF-114
VEGF-114 • Shortest known variant of VEGF • Patent granted • Licensed to MultiGene Vascular Systems (MGVS) for gene and cell therapy in cardiovascular disease • Further validated by MGVS
Slide 12: Cancer Biomarker Engine
Cancer Biomarker Engine Oligo LEADS Microarray Analysis design Identify candidates over- expressed in cancer Quantitative IP RT-PCR Initially validated novel markers
Slide 13: PSA-LM and K-LM
PSA-LM and K-LM Licensed to DPC for diagnostic products J Biol Chem. 2002 May 17;277(20):18084-90
Slide 14: Business Model
Business Model • Industry partnerships around core technologies • Licensing and collaborations with respect to specific discoveries – Internal focus on therapeutic proteins and biomarkers – Joint discovery collaborations
Slide 15: Compugen – A Few Facts
Compugen – A Few Facts • Founded 1993 • IPO August 2000 (Nasdaq: CGEN) • TASE since January 2002 • 140 employees • ~75% R&D, ~30% Ph.D. • Biology and Chemistry wet labs • Facilities: • Tel Aviv, Israel (Ltd. Hdqtrs) • Ashkelon, Israel (Chemistry Project) • Jamesburg, New Jersey (Inc. Hdqtrs) • Rockv
Slide 16: Summary
Summary • Increasing POS of drug discovery through: – Mathematical models and algorithmic approach – Processes that integrate “dry” and “wet” – A better understanding of biological phenomena – Iterative improvements to processes • Quickly established attractive pipeline of therapeutic proteins and b
Slide 17: www.cgen.com
compugen www.cgen.com